Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fulcrum Therapeutics Inc (FULC)

Fulcrum Therapeutics Inc (FULC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 481,650
  • Shares Outstanding, K 54,118
  • Annual Sales, $ 80,000 K
  • Annual Income, $ -9,730 K
  • EBIT $ -82 M
  • EBITDA $ -80 M
  • 60-Month Beta 3.17
  • Price/Sales 5.93
  • Price/Cash Flow N/A
  • Price/Book 2.47

Options Overview Details

View History
  • Implied Volatility 174.67% (+21.94%)
  • Historical Volatility 92.41%
  • IV Percentile 76%
  • IV Rank 33.39%
  • IV High 403.24% on 02/03/25
  • IV Low 60.11% on 08/20/25
  • Expected Move (DTE 13) 3.23 (36.29%)
  • Put/Call Vol Ratio 0.38
  • Today's Volume 2,249
  • Volume Avg (30-Day) 922
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 22,016
  • Open Int (30-Day) 18,956
  • Expected Range 5.67 to 12.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.33
  • Number of Estimates 6
  • High Estimate -0.31
  • Low Estimate -0.37
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -6.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.27 +22.42%
on 11/07/25
12.19 -26.99%
on 11/19/25
+1.03 (+13.09%)
since 11/05/25
3-Month
6.69 +33.03%
on 09/15/25
12.19 -26.99%
on 11/19/25
+1.24 (+16.19%)
since 09/05/25
52-Week
2.32 +283.62%
on 04/07/25
12.19 -26.99%
on 11/19/25
+5.07 (+132.38%)
since 12/05/24

Most Recent Stories

More News
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...

FULC : 8.90 (+1.60%)
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...

FULC : 8.90 (+1.60%)
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ― ― Live and Webcast Investor Event with Fulcrum Leadership and...

FULC : 8.90 (+1.60%)
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

        ― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20...

FULC : 8.90 (+1.60%)
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025

― Preclinical data of FTX-6274 suggests potential for the treatment of castration resistant prostate cancer ― CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ®...

FULC : 8.90 (+1.60%)
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...

FULC : 8.90 (+1.60%)
Leerink Partners Reaffirms Their Buy Rating on Fulcrum Therapeutics (FULC)

Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Fulcrum Therapeutics today and set a price target of $16.00. The company’s shares closed yesterday at $9.24.Elevate Your Investing...

FULC : 8.90 (+1.60%)
Cantor Fitzgerald Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC)

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Fulcrum Therapeutics, with a price target of $15.00. The company’s shares closed yesterday at $9.51.Elevate...

FULC : 8.90 (+1.60%)
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...

FULC : 8.90 (+1.60%)
Fulcrum Therapeutics to Present at Upcoming Investor Meetings

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules...

FULC : 8.90 (+1.60%)

Business Summary

Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on genetically defined diseases with an initial focus on rare diseases. Fulcrum Therapeutics Inc. is based in Cambridge, United States.

See More

Key Turning Points

3rd Resistance Point 10.54
2nd Resistance Point 10.11
1st Resistance Point 9.50
Last Price 8.90
1st Support Level 8.46
2nd Support Level 8.03
3rd Support Level 7.42

See More

52-Week High 12.19
Last Price 8.90
Fibonacci 61.8% 8.42
Fibonacci 50% 7.25
Fibonacci 38.2% 6.09
52-Week Low 2.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar